Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML)

Not Recruiting

Trial ID: NCT00766116

Purpose

This study will test an experimental combination of the drugs Mylotarg and 5-azacitidine in the hopes of finding a treatment that may be effective against Acute Myeloid Leukemia that has come back after treatment.

Official Title

A Phase I/II Trial of the Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed AML

Stanford Investigator(s)

Rondeep Brar
Rondeep Brar

Clinical Associate Professor, Medicine - Hematology

Lauren Maeda
Lauren Maeda

Clinical Associate Professor, Medicine - Oncology

Eligibility


Inclusion Criteria:

   - Diagnosis of Relapsed AML

   - Eastern Cooperative Oncology Group (ECOG) performance status 0-2, and life expectancy
   > 3 months

   - ≥ 18 years old

   - Previously untreated for current AML relapse

   - Adequate organ function

   - Written informed consent

Exclusion Criteria:

   - Pregnant or breast-feeding women

   - Growth factors that support platelet or white cell number or function must not have
   been administered within the past 7 days

   - Currently receiving another investigational drug

   - Currently receiving other anti-cancer agents

   - Uncontrolled infection

   - HIV positive

   - Received previous therapy with either Mylotarg or 5-azacitidine

Intervention(s):

drug: Gemtuzumab ozogamicin

drug: 5-Azacitidine

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office
650-498-7061

New Trial Alerts

Receive email alerts when trials open to patients.